Search Result
Results for "
U937 cells
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0660
-
|
EPA; Timnodonic acid
|
Endogenous Metabolite
Histone Demethylase
|
Neurological Disease
Cancer
|
|
Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .
|
-
-
- HY-17372
-
|
MK 966
|
COX
|
Inflammation/Immunology
Cancer
|
|
Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).
|
-
-
- HY-19619
-
|
|
Phospholipase
Apoptosis
|
Cancer
|
|
m-3M3FBS is a potent phospholipase C (PLC) activator. m-3M3FBS stimulates superoxide generation in human neutrophils, upregulates intracellular calcium concentration, and stimulates inositol phosphate generation in various cell lines. m-3M3FBS induces monocytic leukemia cell apoptosis .
|
-
-
- HY-N0732
-
|
|
IAP
Akt
Caspase
NF-κB
TGF-beta/Smad
JAK
Bacterial
Apoptosis
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis .
|
-
-
- HY-N6703
-
|
(+)-ar-Turmerone
|
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
ar-Turmerone ((+)-ar-Turmerone) is an orally active and major bioactive compound of the herb Curcuma longa with anti-tumorigenesis and anti-inflammatory activities. ar-Turmerone induces apoptosis in U937 cells. ar-Turmerone exerts positive modulation on murine DCs. ar-Turmerone induces NSC proliferation in vitro and in vivo, and can be used for various neurologic disorders study .
|
-
-
- HY-117937
-
BC-1215
2 Publications Verification
|
Ligands for E3 Ligase
|
Inflammation/Immunology
|
|
BC-1215 is a F-box protein 3 (Fbxo3) inhibitor. BC-1215 works by antagonizing of Fbxo3 on TRAF cytokine signaling and exhibits a low IC50 in vitro. BC-1215 can be used for the research of inflammation .
|
-
-
- HY-169996
-
-
-
- HY-131249
-
|
|
MAPKAPK2 (MK2)
|
Inflammation/Immunology
|
|
MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC50 of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC50s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC50s>200 μM). MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo .
|
-
-
- HY-103358
-
KF38789
2 Publications Verification
|
P-selectin
|
Inflammation/Immunology
|
|
KF38789 is a selective inhibitor of P-selectin-PSGL-1 binding. KF38789 inhibits the binding of U937 cells to immobilized P-selectin immunoglobulin G chimeric protein (P-selectin-Ig) with an IC50 value of 1.97 μM .
|
-
-
- HY-113221
-
|
|
Proteasome
Endogenous Metabolite
Apoptosis
|
Metabolic Disease
Cancer
|
|
Isovalerylcarnitine is a metabolite of leucine. Isovalerylcarnitine can specifically activate calpain in human neutrophils. Isovalerylcarnitine inhibits tumor cell proliferation and induces apoptosis. Elevated circulating levels of Isovalerylcarnitine are negatively correlated with reduced lung cancer risk .
|
-
-
- HY-111449
-
BAY-218
2 Publications Verification
AHR antagonist 1
|
Aryl Hydrocarbon Receptor
|
Inflammation/Immunology
Cancer
|
|
BAY-218 (AHR antagonist 1) is an aryl hydrocarbon receptor (AHR) antagonist. BAY-218 has AHR inhibitory activity with an IC50 of 39.9 nM in in U87 glioblastoma cells. BAY-218 can be used for the research of cancer or conditions with dysregulated immune responses .
|
-
-
- HY-171658
-
|
|
PROTACs
Ser/Thr Kinase
TNF Receptor
Toll-like Receptor (TLR)
NF-κB
p38 MAPK
|
Inflammation/Immunology
Cancer
|
|
R1-ICR-5 is a highly selective RIPK1 PROTAC degrader. Mediated by VHL, R1-ICR-5 induces the degradation of RIPK1, which in turn dysregulates the TNFR1 and TLR3/4 signaling hubs, enhances the signaling outputs of NF-κB, MAPK and IFN, and simultaneously promotes RIPK3 activation and necroptosis (necroptosis). R1-ICR-5 can be used in the research of triple-negative breast cancer and skin inflammation .
|
-
-
- HY-149470
-
|
|
Histone Acetyltransferase
|
Cancer
|
|
MOZ-IN-3 (Compound 6j) is a KAT6A (MOZ) acetyltransferase inhibitor (IC50: 30 nM). MOZ-IN-3 has antitumor activity against four different myeloid leukemia cell lines (HL-60, U937, SKNO-1, K562). MOZ-IN-3 has favorable metabolic stability and pharmacokinetics .
|
-
-
- HY-149302
-
MC4033
1 Publications Verification
|
Apoptosis
Autophagy
Histone Acetyltransferase
|
Cancer
|
MC4033 shows IC50s of 39.4 μM, 52.1 μM, 41 μM and 30.1 μM in HCT116, H1299, A549 and U937, respectively .
MC4033 (25, 50, 100, and 200 μM, 72 h) reduces the level of H4K16Ac in HT29 cells, suggesting its ability to inhibit KAT8 in cells .
|
-
-
- HY-108491
-
|
|
SphK
Apoptosis
|
Cancer
|
|
N,N-Dimethylsphingosine is a sphingosine kinase inhibitor. N,N-Dimethylsphingosine binds competitively to sphingosine kinase and blocks the conversion of sphingosine to sphingosine-1-phosphate. N,N-Dimethylsphingosine inhibits sphingosine-1-phosphate release and aggregation of platelets, and also exerts pro-apoptotic effects by resetting ceramide/sphingosine-1-phosphate homeostasis. N,N-Dimethylsphingosine can be used in cancer-related research .
|
-
-
- HY-19393
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
SCH 351591 is a highly selective, orally active PDE4 inhibitor, with IC50 values of 58 nM and 153 nM in humans and rats, respectively. SCH 351591 effectively inhibits pathological processes such as cytokine production, eosinophilia, airway hyperresponsiveness and bronchospasm. SCH 351591 also induces microvascular injury, activates mast cells and endothelial cells, and causes increases in serum histamine and various inflammatory factors, leading to early vascular damage. SCH 351591 has been widely used in studies related to asthma, chronic obstructive pulmonary disease and drug-induced vascular injury .
|
-
-
- HY-B0660R
-
|
EPA (Standard); Timnodonic acid (Standard)
|
Reference Standards
Endogenous Metabolite
Histone Demethylase
|
Neurological Disease
Cancer
|
|
Eicosapentaenoic Acid (Standard) is the analytical standard of Eicosapentaenoic Acid. This product is intended for research and analytical applications. Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .
|
-
-
- HY-146584
-
|
|
Cathepsin
|
Inflammation/Immunology
|
|
Cathepsin C-IN-5 (compound SF38) is a potent, selective and orally active Cathepsin C inhibitor with IC50s of 59.9 nM, 4.26 µM, >5 µM, >5 µM, >5 µM for Cat C, Cat L, Cat S, Cat B, Cat K, respectively. Cathepsin C-IN-5 inhibits the Cat C activity in bone marrow and blood. Cathepsin C-IN-5 decreases the activation of NSPs (neutrophil serine proteases). Cathepsin C-IN-5 shows anti-inflammatory activity .
|
-
-
- HY-138617
-
|
|
RUNX
|
Cancer
|
|
AI-10-47 is a small molecule inhibitor of CBFβ-RUNX binding, with an IC50 of 3.2 μM .
|
-
-
- HY-B1608
-
|
|
|
Cardiovascular Disease
Metabolic Disease
|
|
Chromium chloride is a trivalent chromium compound and an essential trace mineral. Chromium chloride enhances insulin-stimulated GLUT4 translocation and glucose uptake in skeletal muscle. Chromium chloride regulates glucose and lipid metabolism, inhibits TNF-α secretion and oxidative stress in monocytes treated with high glucose or H2O2, and reverses hydrogen peroxide-induced cell growth inhibition. Chromium chloride reduces coronary and aortic lipid deposition and serum cholesterol levels in hypercholesterolemic rabbits. Chromium chloride can be used in research related to diabetes and cardiac atherosclerosis .
|
-
-
- HY-N7926
-
|
|
Environmental Pollutants
Apoptosis
Parasite
TNF Receptor
Interleukin Related
|
Infection
Inflammation/Immunology
|
|
Pentadecane is an orally active natural plant volatile alkane with anti-inflammatory, analgesic, antipyretic and anti-leishmanial activities. Pentadecane presents IC50 values of 65.3 μM, 60.5 μM and 194.8 μM against Leishmania infantum promastigotes, amastigotes and intracellular amastigotes, respectively. Pentadecane downregulates the mRNA expression of TNF-α and IL-12 and inhibits the release of inflammatory mediators. Pentadecane arrests the cell cycle of Leishmania infantum and induces apoptosis. Pentadecane can be applied to the research of inflammation and leishmaniasis .
|
-
-
- HY-N4107
-
|
|
TGF-beta/Smad
|
Infection
Inflammation/Immunology
Cancer
|
|
Phyllanthin is an effective oral anticancer agent. Phyllanthin inhibits MOLT-4 cell viability, increases apoptosis, inhibits cell migration and invasion. Phyllanthin exerts anti-fibrotic effects by down-regulating TGF signaling pathway via ALK5 and Smad2/3. Phyllanthin also has anti-inflammatory and antibacterial properties .
|
-
-
- HY-106784
-
|
|
Fungal
Apoptosis
|
Infection
Cancer
|
|
Ajoene, a garlic-derived compound, is an antithrombotic and antifungal agent. Ajoene inhibits proliferation and induces apoptosis of human leukaemia CD34-negative cells including HL-60, U937, HEL and OCIM-I. Anticancer activities .
|
-
-
- HY-103347
-
|
|
Apoptosis
|
Inflammation/Immunology
|
|
M50054 is a potent inhibitor of apoptosis. M50054 inhibits Etoposide-induced caspase-3 activation of U937 cells with an IC50 of 79 μg/mL. M50054 does not directly inhibit the enzymatic activity of caspase-3. M50054 can be used for the research anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia .
|
-
-
- HY-P1188
-
|
|
Integrin
|
Cancer
|
|
LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC can be used to detect α4β1 integrin affinity .
|
-
-
- HY-173444
-
|
|
HDAC
Transferrin Receptor
Apoptosis
Ferroptosis
|
Cancer
|
|
HDAC11-IN-3 (Compound A9) is a selective HDAC11 inhibitor (IC50: 4.1 nM). HDAC11-IN-3 has inhibitory effects on U937 and OCI-AML2 acute myeloid leukemia (AML) cell lines (IC50: 10 μM). HDAC11-IN-3 has significant anti-AML activity, inducing apoptosis, cell cycle arrest, and differentiation. HDAC11-IN-3 upregulates the iron transporters transferrin (TF) and transferrin receptor (TFRC), and activates the p62-Keap1-Nrf2-HMOX1 pathway, which together lead to increased intracellular iron levels and induce ferroptosis in AML cells. HDAC11-IN-3 can be used alone or in combination with Cytarabine (HY-13605) for AML research .
|
-
-
- HY-106216
-
|
|
Elastase
|
Infection
Inflammation/Immunology
|
|
Tiprelestat is a potent human neutrophil elastase inhibitor. Tiprelestat has antimicrobial and anti-inflammatory activities. Tiprelestat can be used in the research of inflammation/immune disease .
|
-
-
- HY-156694
-
-
-
- HY-N4252
-
|
|
Others
|
Cancer
|
|
Periplocymarin, a cardiac glycoside isolated from Periploca sepium and Periploca graeca, is a potential anti-cancer compound .
|
-
-
- HY-116392D
-
|
|
Glucosylceramide Synthase (GCS)
Apoptosis
|
Cancer
|
|
PDMP hydrochloride is a glucosylceramide synthase (GCS) inhibitor. PDMP hydrochloride induces apoptosis in K562/A02 cells. PDMP hydrochloride can be used in cancer (such as leukemia) research .
|
-
-
- HY-159059
-
|
|
c-Myc
Bcl-2 Family
Eukaryotic Initiation Factor (eIF)
Survivin
β-catenin
MMP
Interleukin Related
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Ganoderma Lucidum/Reishi Extract is a Ganoderma lucidum extract. Ganoderma Lucidum/Reishi Extract reduces the expression of c-Myc, BCL-2, BCL-XL, TERT, PDGFB, eIF4G, Survivin, β-catenin, and eIF4E. Ganoderma Lucidum/Reishi Extract downregulates the gene expression of MMP-9. Ganoderma Lucidum/Reishi Extract upregulates the expression of IL8. Ganoderma Lucidum/Reishi Extract is applicable to the research of inflammatory breast cancer. Ganoderma Lucidum is used in the research of various diseases, such as allergy, arthritis, hypertension, neurasthenia, inflammation, and cancer .
|
-
-
- HY-P3012
-
|
|
Cathepsin
ERK
p38 MAPK
PKC
Protease Activated Receptor (PAR)
MMP
|
Inflammation/Immunology
|
|
Cathepsin G is a pH-dependent serine protease. Cathepsin G hydrolyzes diverse synthetic and protein substrates and remodels extracellular matrix. Cathepsin G exerts immunomodulatory effects via recruiting phagocytes, enhancing T cell motility, activating ERK1/2 and p38 MAPK signaling, and mediating PKCζ membrane translocation. Cathepsin G regulates inflammatory responses by cleaving inflammatory mediators. Cathepsin G participates in vascular regulation by converting angiotensin I to angiotensin II. Cathepsin G induces PAR4-dependent platelet activation, facilitates platelet-neutrophil aggregation, and mediates VITT-related NETosis, thrombus formation. Cathepsin G can be used for the research of immune thrombotic thrombocytopenia, cardiovascular disease, and select autoimmune and inflammatory diseases .
|
-
-
- HY-155552
-
|
|
Apoptosis
CDK
Caspase
|
Cancer
|
|
GSPT1 degrader-1 is a highly selective degrader targeting GSPT1. GSPT1 degrader-1 induces degradation via the ubiquitin-proteasome system. GSPT1 degrader-1 induces G0/G1 phase arrest, apoptosis (apoptosis) and inhibits proliferation in leukemia cells. GSPT1 degrader-1 reduces the levels of CDK6 and Cyclin B1, while increases the levels of activated caspase-3 and caspase-9 in leukemia cells. GSPT1 degrader-1 can be used in leukemia research .
|
-
-
- HY-101556
-
|
CBS-211A
|
Drug Derivative
|
Cancer
|
|
Namirotene (CBS-211A) is a retinoic acid analog, which is utilized in topical eye administration. Namirotene enhances 1α,25-dihydroxyvitamin D3-induced cytotoxicity in cell U937 and induces the differentation in U937 .
|
-
-
- HY-P991517
-
|
|
Transmembrane Glycoprotein
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Cancer
|
|
BI-836858 is a fully human anti-CD33 monoclonal antibody. BI-836858 reduces CD33+ cells via antibody-dependent cellular cytotoxicity (ADCC), blocks downstream signaling of S100A9/CD33, decreases the secretion of immunosuppressive cytokines and reactive oxygen species-induced genomic instability, and restores bone marrow hematopoietic function. BI-836858 is applicable to the research of myelodysplastic syndrome (MDS) and AML .
|
-
-
- HY-105358
-
|
|
Leukotriene Receptor
Calcium Channel
|
Inflammation/Immunology
|
|
CP-288886 is a cysLT1 receptor antagonist with a Ki value of 0.004 μM. CP-288886 exhibits comparable activity to Zafirlukast (HY-17492) and Pranlukast (HY-B0290). CP-288886 inhibits calcium mobilization with an IC50 of 0.0005 μM in human U937 cells. CP-288886 has high oral bioavailability. CP-288886 possesses anti-asthmatic activity in a guinea pig asthma model and can be used for the research of diseases such as asthma .
|
-
-
- HY-147086
-
|
|
Leukotriene Receptor
G protein-coupled Bile Acid Receptor 1
TNF Receptor
|
Metabolic Disease
Inflammation/Immunology
|
|
CAY10789 is a potent CysLT1R (cysteinyl leukotriene receptor 1) antagonist (IC50=2.80 μM) and GPBAR1 (G-protein-coupled bile acid receptor 1) agonist (EC50=3 μM). CAY10789 significantly reduces the adhesion of U937 cells to HAEC, reduces the expression of TNF-α. CAY10789 shows very promising metabolic stability and excellent pharmacokinetics. CAY10789 can be used for the research of colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases .
|
-
-
- HY-W011269
-
|
EPA sodium; Timnodonic acid sodium
|
Endogenous Metabolite
Histone Demethylase
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Eicosapentaenoic Acid (EPA)sodium is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid sodium exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid sodium activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid sodium can promote relaxation of vascular smooth muscle cells and vasodilation .
|
-
-
- HY-135664
-
-
-
- HY-146580
-
|
|
Cathepsin
|
Inflammation/Immunology
|
|
Cathepsin C-IN-3 (compound SF11) is a potent Cathepsin C (Cat C) inhibitor, with an IC50 of 61.79 nM. Cathepsin C-IN-3 also inhibits THP-1 and U937 cell, with IC50 values of 101.5 and 86.5 nM, respectively .
|
-
-
- HY-146581
-
|
|
Cathepsin
|
Inflammation/Immunology
|
|
Cathepsin C-IN-4 (compound SF27) is a potent Cathepsin C (Cat C) inhibitor, with an IC50 of 65.6 nM. Cathepsin C-IN-4 also inhibits THP-1 and U937 cell, with IC50 values of 203.4 and 177.6 nM, respectively .
|
-
-
- HY-120621
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
BMS-229724 is an orally active and tight-binding cytosolic phospholipase A2 (cPLA2) inhibitor with an IC50 of 2.8 μM. BMS-229724 can inhibit the production of arachidonic acid and eicosanoids in U937 cells, neutrophils, platelets, and other cells. BMS-229724 has anti-inflammatory activity and can be used in the research of diseases such as skin inflammation .
|
-
-
- HY-177305
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-inflammatory agent 105 (Compound 12) is an anti-inflammatory compound. The IC50 of Anti-inflammatory agent 105 for the inhibition of TNF-α synthesis and release in the human macrophage cell line U937 is 0.124 nM .
|
-
-
- HY-146758
-
-
-
- HY-13249
-
|
1α-Hydroxy vitamin D4
|
VD/VDR
|
Cancer
|
|
1alpha-Hydroxy VD4, a 1alpha(OH)D derivative, can effectively induce the differentiation of monoblastic leukaemia U937, P39/TSU and P31/FUJ cells.
|
-
-
- HY-162658
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
Leuxinostat is an inhibitor for HDAC with IC50 of 30 nM for hHDAC6. Leuxinostat inhibits the proliferation of cells THP1, K562, U937 and MEK1, induces apoptosis in leukemia cells NB4 and MOLT-4. Leuxinostat inhibits the expansion of hematopoietic stem cells and exhibits antileukemic activity in zebrafish models .
|
-
-
- HY-177304
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-inflammatory agent 104 (Compound 26) is an anti-inflammatory compound. The IC50 of Anti-inflammatory agent 104 for the inhibition of TNF-α synthesis and release in the human macrophage cell line U937 is 0.024 nM. Anti-inflammatory agent 104 can reduce eosinophils in rat lungs by 63% .
|
-
-
- HY-W025074
-
|
|
Sirtuin
Histone Methyltransferase
|
Cancer
|
|
BML-278 is a SIRT1 activator (EC150: 1 μM). BML-278 increases H3K9 methylation and inhibits H3K9 acetylation in both the paternal and maternal pronucleus. BML-278 improves early embryonic development. BML-278 arrests the cell cycle at the G1/S phase, and reduces senescence in primary human mesenchymal cells. BML-278 reduces tubulin acetylation in U937 cells. BML-278 also increases mitochondrial density in murine C2C12 myoblasts .
|
-
-
- HY-177766
-
|
|
Molecular Glues
Apoptosis
|
Cancer
|
|
GSPT1 degrader-17 (Compound 9q) is a potent and selective cereblon-based molecular glue degrader that targets G1 to S phase transition 1 (GSPT1). GSPT1 degrader-17 degrades GSPT1 in U937 cells with a DC50 of 35 nM and Dmax of 81.65%. GSPT1 degrader-17 has a strong inhibitory effect on U937, MOLT-4 and MV4-11 cells with IC50 values of 0.019, 0.006 and 0.027 μM. GSPT1 degrader-17 can induce cells apoptosis and G0/G1 phase arrest. GSPT1 degrader-17 can be used for the research of cancer, such as acute myeloid leukemia .
|
-
-
- HY-17372S
-
|
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
Cancer
|
|
Rofecoxib-d5 is the deuterium labeled Rofecoxib. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells) .
|
-
- HY-173526
-
|
|
Bacterial
Calcium Channel
|
Infection
|
|
H052 is a selective Staphylococcus aureus α-hemolysin (Hla) inhibitor. H052 binds to Hla monomers, disrupts the interaction with host cell membranes to block pore formation, inhibiting calcium ion influx, cytotoxicity, and inflammatory responses. H052 exhibits potency (EC50=30 nM in U937 cells) against Hla-induced calcium influx. H052 is promising for research of lung infections caused by S. aureus .
|
-
- HY-124007
-
|
ISAHA
|
HDAC
|
Cancer
|
|
4-Iodo-SAHA (1k) is an orally active class I and class II histone deacetylase (HDAC) inhibitor with EC50s of 1.1, 0.95, 0.12, 0.24, 0.85 and 1.3 μM for Skbr3, HT29, U937, JA16 and HL60 cell lines, respectively. 4-Iodo-SAHA (1k) can be used for the research of cancer .
|
-
- HY-174380
-
|
|
Dipeptidyl Peptidase
Ser/Thr Protease
Elastase
|
Inflammation/Immunology
|
|
DPP-1-IN-1 (Compound 14) is an orally active inhibitor of Cathepsin C (also known as Dipeptidyl peptidase I) with an IC50 of 5.31 nM. DPP-1-IN-1 can inhibit the activity of Cathepsin C downstream Neutrophil elastase in neutrophils. DPP-1-IN-1 can be used in the research of inflammatory diseases .
|
-
- HY-B0660S1
-
|
EPA 1,2,3,4,5-13C, FA 20:5-13C5
|
Isotope-Labeled Compounds
Endogenous Metabolite
Histone Demethylase
|
Neurological Disease
Cancer
|
|
Eicosapentaenoic acid 1,2,3,4,5- 13C5 (EPA 1,2,3,4,5- 13C, FA 20:5- 13C5) is 13C labeled Eicosapentaenoic Acid. Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .
|
-
- HY-122092
-
|
|
Telomerase
|
Cancer
|
|
FJ-5002 is a telomerase inhibitor with an IC50 of 2 μM. FJ-5002 can induce telomere shortening, increased chromosomal abnormalities, and senescence/crisis-like features in the human leukemia cell line U937. FJ-5002 exhibits antitumor activity and can be used in the study of cancer .
|
-
- HY-162237
-
|
|
RIP kinase
|
Inflammation/Immunology
|
|
RIPK1-IN-13 (compound 28) is a selective inhibitor for receptor-interacting serine/threonine-protein kinase 1 (RIPK1), the inhibitory activity is measured by ADP-Glo Kinase Assay with a pKi of 7.66. RIPK1-IN-13 inhibits human leukaemia cells U937 with a pIC50 of 7.2 .
|
-
- HY-124559
-
|
(Rac)-CHR-3996
|
HDAC
|
Cancer
|
|
(Rac)-Nanatinostat ((Rac)-CHR-3996, example 44) is a potent HDAC inhibitor with an IC50 of <330 nM. (Rac)-Nanatinostat has anticancer effects and can effectively inhibit the cell growth of HeLa, U937 and HUT cells .
|
-
- HY-N6703S
-
|
(+)-ar-Turmerone-d3
|
Isotope-Labeled Compounds
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
ar-Turmerone-d3 is the deuterium labeled ar-Turmerone. ar-Turmerone ((+)-ar-Turmerone) is an orally active and major bioactive compound of the herb Curcuma longa with anti-tumorigenesis and anti-inflammatory activities. ar-Turmerone induces apoptosis in U937 cells. ar-Turmerone exerts positive modulation on murine DCs. ar-Turmerone induces NSC proliferation in vitro and in vivo, and can be used for various neurologic disorders study .
|
-
- HY-143727
-
|
|
RIP kinase
|
Inflammation/Immunology
|
|
RIPK1-IN-9 (example 45), a dihydronaphthyridone compound, is a potent and selective RIPK1 inhibitor. RIPK1-IN-9 inhibits U937 cell (IC50=2 nM) and L929 cell (IC50=1.3 nM) .
|
-
- HY-W747533
-
|
C8 Ceramine; Ceramine (d18:1/8:0)
|
Drug Derivative
|
Others
|
|
C8 Ceramine is an analog of ceramide in which the carbonyl group of the ceramide is replaced by a methylene group. At a concentration of 10 μM, C8 ceramine induces maximal DNA fragmentation in U937 cells after 6 hours of incubation, compared to 12 hours for C8 ceramide.
|
-
- HY-168707
-
|
|
Casein Kinase
|
Cancer
|
|
CK2-IN-14 (Compound 10b) is an inhibitor for cyclin kinase 2α with an IC50 of 36.7 nM. CK2-IN-14 inhibits the growth of cancer cell 786-O and U937 with GI50 of 7.3 μM and 7.5 μM .
|
-
- HY-117782
-
|
|
Others
|
Cancer
|
|
Anticancer agent 236 (compound JP-8g) is a broad-spectrum anticancer agent that has toxic effects on several cancer cell lines with IC50 values of 6.925 μM (MDA), 6.296 μM (U937), 6.548 μM (Jurkat), 6.373 μM (Hela), and 10.381 μM (EJ) .
|
-
- HY-17372R
-
|
MK 966 (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
Cancer
|
|
Rofecoxib (Standard) is the analytical standard of Rofecoxib. This product is intended for research and analytical applications. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).
|
-
- HY-P1188A
-
|
|
Integrin
|
Cancer
|
|
LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC TFA can be used to detect α4β1 integrin affinity .
|
-
- HY-103347R
-
|
|
Reference Standards
Apoptosis
|
Inflammation/Immunology
|
|
M50054 (Standard) is the analytical standard of M50054. This product is intended for research and analytical applications. M50054 is a potent inhibitor of apoptosis. M50054 inhibits Etoposide-induced caspase-3 activation of U937 cells with an IC50 of 79 μg/mL. M50054 does not directly inhibit the enzymatic activity of caspase-3. M50054 can be used for the research anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia .
|
-
- HY-155245
-
|
|
CDK
Bcl-2 Family
|
Cancer
|
|
A09-003 is a CDK-9 inhibitor (IC50: 16 nM). A09-003 inhibits leukemia cell proliferation (IC50: 1.90, 0.86, 2.49, 1.84, 0.48 μM for BDCM, Molm-14, THP-1, U937, MV4-11 cells). A09-003 induces apoptosis and decreases Mcl-1 expression through Thr163 dephosphorylation .
|
-
- HY-159513
-
|
|
Bcl-2 Family
Apoptosis
|
Cancer
|
|
Bcl-2/Mcl-1-IN-4 (compound 20) is a dual inhibitor targeting Bcl-2 (Ki=0.49 μM) and Mcl-1 (Ki=0.51 μM). Bcl-2/Mcl-1-IN-4 significantly inhibits cancer cell proliferation and effectively induces apoptosis in U937 cells. Bcl-2/Mcl-1-IN-4 can be used in cancer research .
|
-
- HY-B0660A
-
|
EPA metformin; Timnodonic acid metformin
|
Endogenous Metabolite
Histone Demethylase
|
Neurological Disease
Cancer
|
|
Eicosapentaenoic Acid (EPA) metformin is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic acid metformin exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). EEicosapentaenoic acid metformin activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic acid metformin can promote relaxation of vascular smooth muscle cells and vasodilation .
|
-
- HY-P5288
-
|
|
Antibiotic
|
Infection
Cancer
|
|
BMAP-28 is an antibiotic peptide and an inducer of the mitochondrial permeability transition pore. BMAP-28 induces cell death through opening of the mitochondrial permeability transition pore. BMAP-28 can be used in study of microbial infections and cancer .
|
-
- HY-150688
-
|
|
JNK
|
Cancer
|
|
JAK3-IN-13 (compound 12n) is a potent, selective and orally active JAK3 inhibitor with IC50 values of 4728, 2039, 8, 365 nM for NK1, JNK2, JNK3, Tyk2, respectively. JAK3-IN-13 shows antiproliferative activity. JAK3-IN-13 induces cell cycle arrest at G0/G1 phase. JAK3-IN-13 shows antitumor activity .
|
-
- HY-169795
-
|
|
Apoptosis
|
Cancer
|
|
C8 D-threo Ceramide (d18:1/8:0) is a sphingolipid analog that can effectively induce apoptosis in U937 cells and cause fragmentation of nucleosomal DNA .
|
-
- HY-138101
-
|
|
COX
|
Inflammation/Immunology
|
|
Desmethyl etoricoxib (example 21) is a selective COX-2 inhibitor with an IC50 of 1 μM in whole blood. Desmethyl etoricoxib inhibits COX-1 with an IC50 of 16 μM in U937 cells. Desmethyl etoricoxib has anti-inflammatory effects .
|
-
- HY-10380
-
|
|
CDK
|
Others
|
|
(R)-DRF053 is a CDK inhibitor. (R)-DRF053 inhibits Cdk5 and promotes the formation of ductal precursor β cells. (R)-DRF053 inhibits Dil-ox-LDL uptake and CD36 gene expression induced by advanced glycation end products (AGEs) in U937 cells .
|
-
- HY-N9284
-
|
|
Others
|
Cancer
|
|
5,19-Epoxy-19R,25-dimethoxycucurbita-6,23-dien-3-ol is a triterpenoid compound derived from Momordica charantia with antitumor activity, exhibiting an IC50 of 32.52 μM against U937 cells. 5,19-Epoxy-19R,25-dimethoxycucurbita-6,23-dien-3-ol shows promise for research in the field of cancer .
|
-
- HY-157040
-
-
- HY-170956
-
|
|
Drug Intermediate
|
Inflammation/Immunology
|
|
BTN3A1 ligand-1 (Compound 26b) is a triazole-containing aryl/acyloxyalkyl phosphonate prodrug. BTN3A1 ligand-1 can stimulate T cell proliferation (EC50 : 0.49 nM) and interferon γ secretion. BTN3A1 ligand-1 has certain plasma stability and can be used in related immunotherapy research .
|
-
- HY-N0732R
-
|
|
Reference Standards
IAP
Akt
Caspase
NF-κB
TGF-beta/Smad
JAK
Bacterial
Apoptosis
|
Infection
Inflammation/Immunology
Cancer
|
|
Jolkinolide B (Standard) is the analytical standard of Jolkinolide B (HY-N0732). This product is intended for research and analytical applications. Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis .
|
-
- HY-135771
-
|
(+)-Avarone
|
Others
|
Cancer
|
|
Avarone ((+)-Avarone) is a sesquiterpenoidal quinone that can be isolated from Dysidea avara. Avarone shows cytotoxicity. Avarone shows antileukemic activity .
|
-
- HY-N13286
-
|
|
Bacterial
|
Infection
|
|
Glycozolidal (compound 12) is a carbazole alkaloid with antibacterial activity against P. gingivalis. Glycozolidal is cytotoxic against human gingival fibroblasts (HGFs) and monocytes (U937) in vitro with IC50 values of 120.86 µg/mL and 97.74 µg/mL, respectively .
|
-
- HY-19619R
-
|
|
Phospholipase
Apoptosis
|
Cancer
|
|
m-3M3FBS (Standard) is the analytical standard of m-3M3FBS. This product is intended for research and analytical applications. m-3M3FBS is a potent phospholipase C (PLC) activator. m-3M3FBS stimulates superoxide generation in human neutrophils, upregulates intracellular calcium concentration, and stimulates inositol phosphate generation in various cell lines. m-3M3FBS induces monocytic leukemia cell apoptosis .
|
-
- HY-B0660S2
-
|
EPA-d10; Timnodonic acid-d10
|
Isotope-Labeled Compounds
Endogenous Metabolite
Histone Demethylase
|
Neurological Disease
Cancer
|
|
Eicosapentaenoic acid-d10 (EPA-d10) is the deuterium labeled Eicosapentaenoic acid (HY-B0660). Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .
|
-
- HY-143900
-
|
|
Btk
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
BTK-IN-7 is a potent and selective inhibitor of BTK (IC50=4.0 nM). BTK-IN-7 has high selectivity in both enzymatic (ITK >250-fold, EGFR >2500-fold) and cellular levels (ITK >227-fold, EGFR 27-fold). BTK-IN-7 also has potent antitumor activity .
|
-
- HY-144755
-
|
|
Histone Demethylase
|
Cancer
|
|
MC2652 (compound 1a) is a potent LSD1 inhibitor. MC2652 displays high inhibiting effects in MV4-11 and NB4 leukaemia cells. MC2652 shows antiproliferative activity against prostate cancer LNCaP cells .
|
-
- HY-161059
-
|
|
RIP kinase
Necroptosis
|
Infection
Inflammation/Immunology
|
|
ZB-R-55 is an orally active and selective dual-mode RIPK1 inhibitor with RIPK1 IC50 values of 5.7 nM. ZB-R-55 occupies both the allosteric and ATP binding sites of RIPK1. ZB-R-55 inhibits necroptosis in cancer cells. ZB-R-55 can be used for the research of systemic inflammatory response syndrome and sepsis .
|
-
- HY-144758
-
|
|
Histone Demethylase
Monoamine Oxidase
|
Cancer
|
|
LSD1-IN-17 (compound 5b) is a potent LSD1 inhibitor. LSD1-IN-17 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC50 values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC50 of 17.2 μM .
|
-
- HY-144756
-
|
|
Histone Demethylase
Monoamine Oxidase
|
Cancer
|
|
LSD1-IN-15 (compound 1b) is a potent LSD1 inhibitor. LSD1-IN-15 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC50 values of 0.149, 0.028, and 0.327 μM, respectively. LSD1-IN-15 displays cell growth arrest in prostate cancer LNCaP cells, with an IC50 of 9.9 μM .
|
-
- HY-144757
-
|
|
Histone Demethylase
Monoamine Oxidase
|
Cancer
|
|
LSD1-IN-16 (compound 4b) is a potent LSD1 inhibitor. LSD1-IN-16 can inhibit LSD1-CoREST, MAO-A and MAO-B, with IC50 values of 0.015, 0.024, and 0.366 μM, respectively. LSD1-IN-16 displays cell growth arrest in prostate cancer LNCaP cells, with an IC50 of 15.2 μM .
|
-
- HY-N4107R
-
|
|
Reference Standards
TGF-beta/Smad
|
Infection
Inflammation/Immunology
Cancer
|
|
Phyllanthin (Standard) is the analytical standard of Phyllanthin. This product is intended for research and analytical applications. Phyllanthin is an effective oral anticancer agent. Phyllanthin inhibits MOLT-4 cell viability, increases apoptosis, inhibits cell migration and invasion. Phyllanthin exerts anti-fibrotic effects by down-regulating TGF signaling pathway via ALK5 and Smad2/3. Phyllanthin also has anti-inflammatory and antibacterial properties .
|
-
- HY-N1328
-
|
|
Others
|
Cancer
|
|
Safrolglycol is a phenylpropane compound that can be found in the wood of Cinnamomum parthenoxylon. Safrolglycol inhibits the proliferation of human leukemia cells and can be used in leukemia-related research .
|
-
- HY-181898
-
|
|
PROTACs
IRAK
|
Inflammation/Immunology
|
|
PROTAC IRAK3 degrader-2 (Compound 17) is a IRAK3 PROTAC degrader with a DC50 ≤ 50 nM. It promotes ubiquitination and degradation of IRAK3, and is applicable to the research of immune diseases .
|
-
- HY-182957
-
|
|
MNK
Pim
Apoptosis
Caspase
Eukaryotic Initiation Factor (eIF)
PARP
c-Myc
|
Cancer
|
|
MNK/PIM-IN-2 is a Mnk/Pim kinase inhibitor with an IC50 of 32 nM for Mnk1, 3 nM for Mnk2, and 37 nM for Pim1. MNK/PIM-IN-2 reduces the levels of p-eIF4E and p-4EBP1. MNK/PIM-IN-2 induces cell cycle arrest, apoptosis (apoptosis) and exerts antiproliferative effects in leukemia cells. MNK/PIM-IN-2 can be used in studies related to leukemia .
|
-
- HY-181949
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
PROTAC BRD9 Degrader-10 is a PROTAC degrader targeting BRD9, with an IC50 of 2.97 μM against BRD9. PROTAC BRD9 Degrader-10 induces BRD9 degradation via the ubiquitin-proteasome system by recruiting the VHL E3 ubiquitin ligase. PROTAC BRD9 Degrader-10 reduces the viability and inhibits the proliferation of myeloid leukemia cells. PROTAC BRD9 Degrader-10 is applicable for the research of acute myeloid leukemia .
|
-
- HY-181596
-
|
|
RIP kinase
Mixed Lineage Kinase
Apoptosis
|
Inflammation/Immunology
|
|
WJH-C19 is an orally active RIPK1 inhibitor with an IC50 of 5.7 nM. WJH-C19 inhibits the RIPK1/RIPK3/MLKL signaling axis, blocks RIPK1 phosphorylation, suppresses the phosphorylation of downstream RIPK3 and MLKL, disrupts necrosome formation, and exhibits protective effects against necroptosis (Apoptosis) in multiple cell lines. WJH-C19 ameliorates symptoms of inflammatory bowel disease in a mouse colitis model by regulating the necroptosis pathway. WJH-C19 alleviates inflammation and bone destruction in a mouse model of rheumatoid arthritis. WJH-C19 is applicable to research related to inflammatory bowel disease and rheumatoid arthritis .
|
-
- HY-P992162
-
|
|
Orexin Receptor (OX Receptor)
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
23ME-00610 is a humanized effector-function-null IgG1 antibody targeting CD200R1, with a Kd of <0.1 nM for hCD200R1. 23ME-00610 blocks the binding of CD200 to CD200R1 and inhibits the recruitment of the downstream adaptor protein DOK2 to CD200R1. 23ME-00610 restores IL-2 production suppressed by CD200. 23ME-00610 induces cytokine production in cells. 23ME-00610 enhances cell-mediated tumor cell killing in vitro. 23ME-00610 can be used for melanoma research .
|
-
- HY-181951
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
PROTAC BRD9 Degrader-11 is a VHL-based BRD9 PROTAC degraderwith an IC50 of 0.66 μM. PROTAC BRD9 Degrader-11 induces selective, proteasome-dependent degradation of BRD9 via the ubiquitin-proteasome system. PROTAC BRD9 Degrader-11 impairs cell viability, suppresses proliferation, and arrests growth of acute myeloid leukemia cells. PROTAC BRD9 Degrader-11 can be used for the research of acute myeloid leukemia .
|
-
- HY-181078
-
|
|
c-Myc
Apoptosis
Bcl-2 Family
|
Cancer
|
|
Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph (3,4OMe) is an anti-leukemic agent with potent ribosome-targeting protein synthesis inhibition. Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph (3,4OMe) downregulates short-lived oncoproteins, including c-Myc and Mcl-1, by inhibiting protein synthesis. Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph (3,4OMe) induces cell cycle arrest at the G0/G1 phase and triggers mitochondrial pathway-mediated apoptosis in acute myeloid leukemia (AML) cells. Cephalotaxine-ester-(R)-1-ethoxy-3-mercaptopropan-2-ol-Ph (3,4OMe) is applicable for research on leukemia .
|
-
- HY-P11759
-
|
|
Drug Derivative
|
Cancer
|
|
Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .
|
-
- HY-182644
-
|
|
Toll-like Receptor (TLR)
NF-κB
TNF Receptor
Interleukin Related
|
Cancer
|
|
SMU-Z1 is a TLR1/2 heterodimer agonist with an EC50 of 4.88 nM. SMU-Z1 activates the NF-κB pathway, triggers pro-inflammatory cytokine production, and induces the generation of TNF-α, IL-1β, IL-6 and NO. SMU-Z1 promotes splenocyte proliferation and upregulates the expression of CD8 +T cells, NK cells and dendritic cells. SMU-Z1 exhibits significant anti-tumor effects in mouse leukemia models. SMU-Z1 can be used for leukemia-related research .
|
-
- HY-181513
-
|
|
Interleukin Related
TNF Receptor
|
Inflammation/Immunology
|
|
DPP-1-IN-2 is a DPP-I inhibitor with a human IC50 of 36.8 nM and oral efficacy. DPP-1-IN-2 binds to intracellular DPP-I, increases its thermal stability, and reduces the activity and expression levels of downstream neutrophil serine proteases by inhibiting its enzymatic activity. DPP-1-IN-2 regulates the secretion of inflammatory factors and chemokines to exert anti-inflammatory effects. DPP-1-IN-2 reverses joint inflammation and tissue damage in adjuvant-induced arthritis rat models. DPP-1-IN-2 is applicable to research related to arthritis .
|
-
- HY-D3274
-
|
|
Fluorescent Dye
|
Others
|
|
PE-Cy5 is a tandem fluorescent dye commonly used in flow cytometry, immunofluorescence, and cell biology research. It is formed by the covalent linkage of two fluorescent molecules, namely phycoerythrin and CY5. PE-Cy5 binds to human FcγRI (CD64), and this binding can be blocked by human pooled serum, anti-CD64 monoclonal antibodies targeting the ligand-binding region, or aggregated IgG. PE-Cy5 supports three-color flow cytometry analysis, and whole blood staining can partially reduce its non-specific binding (Ex/Em = 450-500 nm/665 nm) .
|
-
- HY-N0660
-
|
|
Apoptosis
PARP
Caspase
AMPK
Autophagy
VEGFR
Keap1-Nrf2
STING
11β-HSD
Ferroptosis
PI3K
Akt
p38 MAPK
ERK
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .
|
-
- HY-13495
-
ML281
2 Publications Verification
|
STK33
PKA
Aurora Kinase
Bcl-2 Family
Apoptosis
|
Metabolic Disease
Cancer
|
|
ML281 is a highly selective inhibitor of serine/threonine kinase 33 (STK33) with an IC50 value of 14 nM. ML281 shows 700-fold selectivity over PKA and 550-fold over AurB. ML281 exerts core mechanism by inhibiting STK33: in small cell lung cancer, ML281 downregulates RPS6/BAD signaling phosphorylation, induces apoptosis, and suppresses proliferation, invasion . ML281 reduces STK33-mediated 4-hydroxyphenylpyruvate dioxygenase (HPD) phosphorylation in tyrosinemia . ML281 is suitable for research on STK33 function, KRAS mutation-related cancers (pancreatic cancer, colon cancer, lung adenocarcinoma, etc.), small cell lung cancer, and tyrosinemia-related damage
|
-
- HY-180416
-
|
|
Antibiotic
|
Cancer
|
|
TMC-169 is a potent antibiotic of the Aspochalasin group that can be isolated from Aspergillus flavipes. TMC-169 exhibits anti-tumor activity against multiple cancer cells. TMC-169 can be used for the research of cancer, such as hematologic malignancies, non-small cell lung cancer, breast cancer, and glioma .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D3274
-
|
|
Fluorescent Dyes
|
|
PE-Cy5 is a tandem fluorescent dye commonly used in flow cytometry, immunofluorescence, and cell biology research. It is formed by the covalent linkage of two fluorescent molecules, namely phycoerythrin and CY5. PE-Cy5 binds to human FcγRI (CD64), and this binding can be blocked by human pooled serum, anti-CD64 monoclonal antibodies targeting the ligand-binding region, or aggregated IgG. PE-Cy5 supports three-color flow cytometry analysis, and whole blood staining can partially reduce its non-specific binding (Ex/Em = 450-500 nm/665 nm) .
|
| Cat. No. |
Product Name |
Type |
-
- HY-159059
-
|
|
Biochemical Assay Reagents
|
|
Ganoderma Lucidum/Reishi Extract is a Ganoderma lucidum extract. Ganoderma Lucidum/Reishi Extract reduces the expression of c-Myc, BCL-2, BCL-XL, TERT, PDGFB, eIF4G, Survivin, β-catenin, and eIF4E. Ganoderma Lucidum/Reishi Extract downregulates the gene expression of MMP-9. Ganoderma Lucidum/Reishi Extract upregulates the expression of IL8. Ganoderma Lucidum/Reishi Extract is applicable to the research of inflammatory breast cancer. Ganoderma Lucidum is used in the research of various diseases, such as allergy, arthritis, hypertension, neurasthenia, inflammation, and cancer .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1188
-
|
|
Integrin
|
Cancer
|
|
LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC can be used to detect α4β1 integrin affinity .
|
-
- HY-106216
-
|
|
Elastase
|
Infection
Inflammation/Immunology
|
|
Tiprelestat is a potent human neutrophil elastase inhibitor. Tiprelestat has antimicrobial and anti-inflammatory activities. Tiprelestat can be used in the research of inflammation/immune disease .
|
-
- HY-P3012
-
|
|
Cathepsin
ERK
p38 MAPK
PKC
Protease Activated Receptor (PAR)
MMP
|
Inflammation/Immunology
|
|
Cathepsin G is a pH-dependent serine protease. Cathepsin G hydrolyzes diverse synthetic and protein substrates and remodels extracellular matrix. Cathepsin G exerts immunomodulatory effects via recruiting phagocytes, enhancing T cell motility, activating ERK1/2 and p38 MAPK signaling, and mediating PKCζ membrane translocation. Cathepsin G regulates inflammatory responses by cleaving inflammatory mediators. Cathepsin G participates in vascular regulation by converting angiotensin I to angiotensin II. Cathepsin G induces PAR4-dependent platelet activation, facilitates platelet-neutrophil aggregation, and mediates VITT-related NETosis, thrombus formation. Cathepsin G can be used for the research of immune thrombotic thrombocytopenia, cardiovascular disease, and select autoimmune and inflammatory diseases .
|
-
- HY-P1188A
-
|
|
Integrin
|
Cancer
|
|
LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC TFA can be used to detect α4β1 integrin affinity .
|
-
- HY-P5288
-
|
|
Antibiotic
|
Infection
Cancer
|
|
BMAP-28 is an antibiotic peptide and an inducer of the mitochondrial permeability transition pore. BMAP-28 induces cell death through opening of the mitochondrial permeability transition pore. BMAP-28 can be used in study of microbial infections and cancer .
|
-
- HY-P11759
-
|
|
Drug Derivative
|
Cancer
|
|
Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P991517
-
|
|
Transmembrane Glycoprotein
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Cancer
|
|
BI-836858 is a fully human anti-CD33 monoclonal antibody. BI-836858 reduces CD33+ cells via antibody-dependent cellular cytotoxicity (ADCC), blocks downstream signaling of S100A9/CD33, decreases the secretion of immunosuppressive cytokines and reactive oxygen species-induced genomic instability, and restores bone marrow hematopoietic function. BI-836858 is applicable to the research of myelodysplastic syndrome (MDS) and AML .
|
-
(5)
-
- HY-P992162
-
|
|
Orexin Receptor (OX Receptor)
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
23ME-00610 is a humanized effector-function-null IgG1 antibody targeting CD200R1, with a Kd of <0.1 nM for hCD200R1. 23ME-00610 blocks the binding of CD200 to CD200R1 and inhibits the recruitment of the downstream adaptor protein DOK2 to CD200R1. 23ME-00610 restores IL-2 production suppressed by CD200. 23ME-00610 induces cytokine production in cells. 23ME-00610 enhances cell-mediated tumor cell killing in vitro. 23ME-00610 can be used for melanoma research .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-B0660
-
-
-
- HY-N0732
-
|
|
Structural Classification
Euphorbia fischeriana Steud.
Classification of Application Fields
Terpenoids
Diterpenoids
Euphorbiaceae
Plants
Disease Research Fields
Cancer
|
IAP
Akt
Caspase
NF-κB
TGF-beta/Smad
JAK
Bacterial
Apoptosis
|
|
Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis .
|
-
-
- HY-N6703
-
-
-
- HY-113221
-
-
-
- HY-N0660
-
|
|
Cardiovascular Disease
Triterpenes
Structural Classification
other families
Classification of Application Fields
Terpenoids
Plants
Disease Research Fields
Source Classification
|
Apoptosis
PARP
Caspase
AMPK
Autophagy
VEGFR
Keap1-Nrf2
STING
11β-HSD
Ferroptosis
PI3K
Akt
p38 MAPK
ERK
|
|
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .
|
-
-
- HY-B0660R
-
-
-
- HY-N7926
-
-
-
- HY-N4107
-
-
-
- HY-106784
-
-
-
- HY-N4252
-
-
-
- HY-W011269
-
-
-
- HY-N9284
-
-
-
- HY-N0732R
-
|
|
Structural Classification
Euphorbia fischeriana Steud.
Terpenoids
Diterpenoids
Euphorbiaceae
Plants
|
Reference Standards
IAP
Akt
Caspase
NF-κB
TGF-beta/Smad
JAK
Bacterial
Apoptosis
|
|
Jolkinolide B (Standard) is the analytical standard of Jolkinolide B (HY-N0732). This product is intended for research and analytical applications. Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis .
|
-
-
- HY-135771
-
-
-
- HY-N13286
-
-
-
- HY-N4107R
-
-
-
- HY-N1328
-
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-17372S
-
|
|
|
Rofecoxib-d5 is the deuterium labeled Rofecoxib. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells) .
|
-
-
- HY-B0660S1
-
|
|
|
Eicosapentaenoic acid 1,2,3,4,5- 13C5 (EPA 1,2,3,4,5- 13C, FA 20:5- 13C5) is 13C labeled Eicosapentaenoic Acid. Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .
|
-
-
- HY-N6703S
-
|
|
|
ar-Turmerone-d3 is the deuterium labeled ar-Turmerone. ar-Turmerone ((+)-ar-Turmerone) is an orally active and major bioactive compound of the herb Curcuma longa with anti-tumorigenesis and anti-inflammatory activities. ar-Turmerone induces apoptosis in U937 cells. ar-Turmerone exerts positive modulation on murine DCs. ar-Turmerone induces NSC proliferation in vitro and in vivo, and can be used for various neurologic disorders study .
|
-
-
- HY-B0660S2
-
|
|
|
Eicosapentaenoic acid-d10 (EPA-d10) is the deuterium labeled Eicosapentaenoic acid (HY-B0660). Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: